Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling

[1]  R. Branicky,et al.  Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling , 2018, The Journal of cell biology.

[2]  J. Dickenson,et al.  Role of transglutaminase 2 in A1 adenosine receptor‐ and &bgr;2‐adrenoceptor‐mediated pharmacological pre‐ and post‐conditioning against hypoxia‐reoxygenation‐induced cell death in H9c2 cells , 2018, European journal of pharmacology.

[3]  Nikhat Saleem,et al.  Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat , 2017, Molecular and Cellular Biochemistry.

[4]  M. Harper,et al.  Cellular redox dysfunction in the development of cardiovascular diseases. , 2017, Biochimica et biophysica acta. General subjects.

[5]  G. Condorelli,et al.  Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure , 2017, Proceedings of the National Academy of Sciences.

[6]  Takafumi Suzuki,et al.  Stress-sensing mechanisms and the physiological roles of the Keap1–Nrf2 system during cellular stress , 2017, The Journal of Biological Chemistry.

[7]  J. Furness,et al.  Costorage of Enteroendocrine Hormones Evaluated at the Cell and Subcellular Levels in Male Mice , 2017, Endocrinology.

[8]  S. Goswami,et al.  Activation of adrenergic receptor in H9c2 cardiac myoblasts co-stimulates Nox2 and the derived ROS mediate the downstream responses , 2017, Molecular and Cellular Biochemistry.

[9]  S. Mahata,et al.  Catestatin: A Master Regulator of Cardiovascular Functions. , 2017, Current medicinal chemistry.

[10]  Ying Liang,et al.  Catestatin-A Novel Predictor of Left Ventricular Remodeling After Acute Myocardial Infarction , 2017, Scientific Reports.

[11]  S. Mahata,et al.  Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity , 2017, Front. Endocrinol..

[12]  S. Weber,et al.  Role of protein phosphatase inhibitor-1 in cardiac beta adrenergic pathway. , 2016, Journal of molecular and cellular cardiology.

[13]  M. Barančík,et al.  Nrf2 as a key player of redox regulation in cardiovascular diseases. , 2016, Physiological research.

[14]  V. Mohan,et al.  Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway , 2016, Hypertension.

[15]  Q. Cui,et al.  Catestatin attenuates endoplasmic reticulum induced cell apoptosis by activation type 2 muscarinic acetylcholine receptor in cardiac ischemia/reperfusion , 2015, Scientific Reports.

[16]  F. Scavello,et al.  The NO stimulator, Catestatin, improves the Frank-Starling response in normotensive and hypertensive rat hearts. , 2015, Nitric oxide : biology and chemistry.

[17]  C. Qiang,et al.  Puerarin Suppresses Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting NADPH Oxidase Activation and Oxidative Stress-Triggered AP-1 Signaling Pathways. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[18]  Gina Manda,et al.  The redox biology network in cancer pathophysiology and therapeutics , 2015, Redox biology.

[19]  C. Gallina,et al.  Catestatin Exerts Direct Protective Effects on Rat Cardiomyocytes Undergoing Ischemia/Reperfusion by Stimulating PI3K-Akt-GSK3β Pathway and Preserving Mitochondrial Membrane Potential , 2015, PloS one.

[20]  B. Tota,et al.  Cardio-vascular activity of catestatin: interlocking the puzzle pieces. , 2014, Current medicinal chemistry.

[21]  Dan-dan Zhu,et al.  The important role of catestatin in cardiac remodeling , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[22]  Peter C. Hollenhorst,et al.  Extracellular Signal-Regulated Kinase Signaling Regulates the Opposing Roles of JUN Family Transcription Factors at ETS/AP-1 Sites and in Cell Migration , 2014, Molecular and Cellular Biology.

[23]  W. Leonard,et al.  Complex interactions of transcription factors in mediating cytokine biology in T cells , 2014, Immunological reviews.

[24]  T. Angelone,et al.  The surging role of Chromogranin A in cardiovascular homeostasis , 2014, Front. Chem..

[25]  D. Leosco,et al.  Adrenal adrenoceptors in heart failure , 2014, Front. Physiol..

[26]  M. Piepoli,et al.  Low Serum Ferroxidase I Activity Is Associated With Mortality in Heart Failure and Related to Both Peroxynitrite-Induced Cysteine Oxidation and Tyrosine Nitration of Ceruloplasmin , 2014, Circulation research.

[27]  J. Rehfeld,et al.  Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure , 2014, Endocrine connections.

[28]  J. Engelhardt,et al.  The Basic Biology of Redoxosomes in Cytokine-Mediated Signal Transduction and Implications for Disease-Specific Therapies , 2014, Biochemistry.

[29]  A. Baker,et al.  Cardiac Alpha1-Adrenergic Receptors: Novel Aspects of Expression, Signaling Mechanisms, Physiologic Function, and Clinical Importance , 2014, Pharmacological Reviews.

[30]  L. D. de Windt,et al.  Regulation of fetal gene expression in heart failure. , 2013, Biochimica et biophysica acta.

[31]  G. Sumara,et al.  The AP-1 Transcription Factor c-Jun Prevents Stress-Imposed Maladaptive Remodeling of the Heart , 2013, PloS one.

[32]  A. Lymperopoulos.  Physiology and pharmacology of the cardiovascular adrenergic system , 2013, Front. Physiol..

[33]  P. Ferdinandy,et al.  Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. , 2013, Cardiovascular research.

[34]  M. Nováková,et al.  Hydroxyl radicals' production and ECG parameters during ischemia and reperfusion in rat, guinea pig and rabbit isolated heart. , 2013, General physiology and biophysics.

[35]  Xintian Zhang,et al.  A Switch Role of Src in the Biphasic EGF Signaling of ER-Negative Breast Cancer Cells , 2012, PloS one.

[36]  Howon Lee,et al.  Catestatin (Chromogranin A352–372) and Novel Effects on Mobilization of Fat from Adipose Tissue through Regulation of Adrenergic and Leptin Signaling* , 2012, The Journal of Biological Chemistry.

[37]  Y. Loh,et al.  Chromogranin A and Derived Peptides in Health and Disease , 2012, Journal of Molecular Neuroscience.

[38]  P. Pilowsky,et al.  Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM. , 2012, American journal of physiology. Regulatory, integrative and comparative physiology.

[39]  S. Goswami,et al.  In cardiac myoblasts, cellular redox regulates FosB and Fra-1 through multiple cis-regulatory modules. , 2011, Free radical biology & medicine.

[40]  T. O’Connell,et al.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. , 2011, Journal of molecular and cellular cardiology.

[41]  S. Rong,et al.  The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor–Dependent Mechanism , 2010, Circulation research.

[42]  D. O'Connor,et al.  Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in Humans In Vivo , 2010, Clinical and experimental hypertension.

[43]  João V. Rodrigues,et al.  Enhanced superoxide and hydrogen peroxide detection in biological assays. , 2010, Free radical biology & medicine.

[44]  D. O'Connor,et al.  Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses , 2010, Journal of hypertension.

[45]  D. O'Connor,et al.  Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. , 2009, Endocrinology.

[46]  B. Brar,et al.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. , 2008, Endocrinology.

[47]  D. O'Connor,et al.  The Crucial Role of Chromogranins in Storage and Exocytosis Revealed Using Chromaffin Cells from Chromogranin A Null Mouse , 2008, The Journal of Neuroscience.

[48]  Yan Gu,et al.  Downregulation of CuZn-superoxide dismutase contributes to beta-adrenergic receptor-mediated oxidative stress in the heart. , 2007, Cardiovascular research.

[49]  S. Goswami,et al.  An assessment of the role of reactive oxygen species and redox signaling in norepinephrine-induced apoptosis and hypertrophy of H9c2 cardiac myoblasts. , 2006, Antioxidants & redox signaling.

[50]  L. Johnston,et al.  Imaging nanometer domains of β-adrenergic receptor complexes on the surface of cardiac myocytes , 2005, Nature chemical biology.

[51]  D. Sawyer,et al.  Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. , 2005, Journal of cardiac failure.

[52]  K. Iwatsubo,et al.  Accumulation of molecules involved in alpha1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. , 2001, Cardiovascular research.

[53]  S. Marklund,et al.  Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. , 1974, European journal of biochemistry.

[54]  K. Helle,et al.  Chromogranins: from discovery to current times , 2017, Pflügers Archiv - European Journal of Physiology.

[55]  K. Helle,et al.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology , 2014, Cellular and Molecular Life Sciences.

[56]  J. Rehfeld,et al.  Chromogranin A as a biomarker in cardiovascular disease. , 2014, Biomarkers in medicine.

[57]  S. Mahata,et al.  Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. , 2012, American journal of physiology. Heart and circulatory physiology.

[58]  Han Xiao,et al.  Beta-adrenoceptor signaling pathways mediate cardiac pathological remodeling. , 2012, Frontiers in bioscience.

[59]  J. Pincemail,et al.  [Oxidative stress]. , 2007, Revue medicale de Liege.

[60]  M. Kazanietz,et al.  Further evidence of interaction between vasodilator beta 2- and vasoconstrictor alpha 2-adrenoceptor-mediated responses in maintaining vascular tone in anesthetized rats. , 1989, Journal of cardiovascular pharmacology.